We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+30.01%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.81B
AUM Growth
+$199M
(+7.6%)
Cap. Flow
-$124M
Cap. Flow
% of AUM
-4.42%
Top 10 Holdings %
Top 10 Hldgs %
33.19%
Holding
104
New
32
Increased
17
Reduced
29
Closed
17
Top Buys
| 1 |
Illumina
ILMN
|
+$63.9M |
| 2 |
Merck
MRK
|
+$61.9M |
| 3 |
Cigna
CI
|
+$60.7M |
| 4 |
CG Oncology
CGON
|
+$59.4M |
| 5 |
Intuitive Surgical
ISRG
|
+$53.3M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
+$81.9M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$65.2M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
+$54.2M |
| 4 |
Biohaven
BHVN
|
+$53.1M |
| 5 |
Zoetis
ZTS
|
+$47.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITCI
1
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $239M | 8.51% |
+600,000
| New | +$41.2M |
|
|
FUSN
2
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $139M | 4.93% |
6,500,328
| – | – |
|
3
Boston Scientific
BSX
$64B
| $134M | 4.76% |
1,956,000
+66,000
| +3% | +$4.24M |
|
4
Arvinas
ARVN
$534M
| $123M | 4.38% |
2,985,190
+73
| +0% | +$3.19K |
|
|
5
Intuitive Surgical
ISRG
$138B
| $90.2M | 3.21% |
226,000
+141,000
| +166% | +$53.3M |
|
6
Dianthus Therapeutics
DNTH
$5.46B
| $81.5M | 2.9% |
2,717,554
+1,500,000
| +123% | +$32.6M |
|
7
Acadia Healthcare
ACHC
$2.97B
| $79.6M | 2.83% |
1,005,000
-151,692
| -13% | -$12.4M |
|
8
Neurocrine Biosciences
NBIX
$17.3B
| $74M | 2.63% |
536,500
-121,500
| -18% | -$16.6M |
|
9
Natera
NTRA
$39.7B
| $73.5M | 2.61% |
803,300
-306,700
| -28% | -$23.1M |
|
10
Jazz Pharmaceuticals
JAZZ
$15B
| $70.3M | 2.5% |
584,000
+94,881
| +19% | +$11.6M |
|
11
Avantor
AVTR
$7.65B
| $68.9M | 2.45% |
2,695,000
+573,156
| +27% | +$13.6M |
|
|
12
Cigna
CI
$78.8B
| $67M | 2.38% |
+184,500
| New | +$60.7M |
|
|
13
Merck
MRK
$305B
| $66.2M | 2.35% |
+502,000
| New | +$61.9M |
|
14
Regeneron Pharmaceuticals
REGN
$69.7B
| $65.4M | 2.33% |
68,000
| – | – |
|
|
15
CG Oncology
CGON
$6.44B
| $63.9M | 2.27% |
+1,454,765
| New | +$59.4M |
|
|
16
Illumina
ILMN
$28.3B
| $63.7M | 2.27% |
+477,095
| New | +$63.9M |
|
17
Tenet Healthcare
THC
$16.6B
| $63.2M | 2.25% |
601,000
-270,000
| -31% | -$24.3M |
|
18
Align Technology
ALGN
$13B
| $62M | 2.2% |
189,000
+33,200
| +21% | +$9.74M |
|
19
Syndax Pharmaceuticals
SNDX
$2.08B
| $57.4M | 2.04% |
2,412,500
-1,537,500
| -39% | -$34.3M |
|
20
Eli Lilly
LLY
$1.03T
| $54.5M | 1.94% |
70,000
-15,000
| -18% | -$10.7M |
|
21
United Therapeutics
UTHR
$22.6B
| $49.8M | 1.77% |
217,000
-20,202
| -9% | -$4.56M |
|
|
ALPN
22
DELISTED
Alpine Immune Sciences Inc
ALPN
| $46.6M | 1.66% |
+1,174,700
| New | +$34.7M |
|
23
Ultragenyx Pharmaceutical
RARE
$3.12B
| $43.6M | 1.55% |
933,500
+89,000
| +11% | +$4.2M |
|
24
CVS Health
CVS
$135B
| $43.5M | 1.55% |
545,000
-195,000
| -26% | -$14.9M |
|
25
Surgery Partners
SGRY
$2.08B
| $43.1M | 1.53% |
1,445,000
+279,068
| +24% | +$8.73M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH